ArticleCHEST pulmonary2026
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration With 19-Gauge vs 21- or 22-Gauge Needle for Mediastinal Lymphadenopathy: An Updated Analysis of the SCOPE Database.
Article in CHEST pulmonary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has been established as safe and effective in evaluating the mediastinum for malignant lymphadenopathy, with sensitivity reported at 92% to 95% with 21- and 22-gauge endobronchial ultrasound (EBUS) needles. Results for lymphoma and benign conditions such as sarcoidosis are significantly lower. Research Question: Does a 19-gauge EBUS needle increase diagnostic performance over smaller needles (21 or 22 gauge) in patients with a preprocedural diagnosis of suspected sarcoidosis, lymphoma, or mediastinal lymphadenopathy not yet diagnosed? Study Design and Methods: This study retrospectively examined patient records from the Stather Canadian Outcomes Registry for Chest Procedures database, and included patients who underwent EBUS-TBNA for a preprocedural diagnosis of suspected sarcoidosis, lymphoma, or mediastinal lymphadenopathy not yet diagnosed. Patients were separated into those who received EBUS-TBNA with a 19-gauge vs 21-/22-gauge needle. We performed a propensity score matching analysis with a 1:2 ratio and an inverse probability of treatment weighting approach, with diagnostic yield (DY) as the primary end point. Results: The data set was extracted from the Stather Canadian Outcomes Registry for Chest Procedures database on July 1, 2023, and included 1,810 procedures (19-gauge group: n = 195; 21-/22-gauge group: n = 1,615). The DY of EBUS-TBNA procedures with propensity score matching analysis was 230 of 316 (72.8%) in the 21-/22-gauge group vs 116 of 158 (73.4%) in the 19-gauge group (difference, 0.6%; 95% CI, -8.1 to 8.7%; Interpretation: We did not identify a statistically significant difference in DY between the 19-gauge EBUS needles over the 21-/22-gauge needles in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.